Mereo BioPharma MREO
NASDAQ MREO
$0.31 +0.01 (+2.92%)
At close: Nov 11, 2026 · 4:00 PM EST

Mereo BioPharma (MREO) Short term Debt (2022)

Updated

Mereo BioPharma (MREO) reported Short term Debt of $20.09 million for Q2 2022.

Analysis

Mereo BioPharma (MREO) Short term Debt (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Mereo BioPharma 47.91 Mn -79.40 Mn 800,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 19.35 Mn
API Access

Mereo BioPharma Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=MREO&period=max&api_key=YOUR_API_KEY